(Funded by the National Institutes of Health)
Researchers at the University of Notre Dame have developed an automated device that can diagnose glioblastoma, an incurable brain cancer, in less than an hour. The device features a biochip that uses a sensor that detects biomarkers, called active Epidermal Growth Factor Receptors (EGFRs), that are overexpressed in glioblastoma. EGFRs are found on extracellular vesicles – structures that carry cargo between cells. The device also features silica nanoparticles that report the presence of active EGFRs on the captured extracellular vesicles, while bringing a high negative charge.

(Funded by the National Institutes of Health)
Researchers from Caltech, the University of Washington, the University of Pennsylvania, the University at Albany, the Rockefeller University, the University of Edinburgh, Creative BioSolutions, LLC (Miami, FL), HDT Bio (Seattle, WA), Acuitas Therapeutics (Vancouver, Canada), and Ingenza Ltd. (RoslIn, United Kingdom) have developed and tested a new COVID-19 vaccine candidate called mosaic-8 that has shown potential to protect against different types of sarbecoviruses, including SARS-CoV-2 (the virus that causes COVID-19) and its variants. The mosaic-8 vaccine is made up of nanoparticles that elicit antibodies against conserved features of sarbecoviruses. Each nanoparticle contains pieces of eight different sarbecoviruses. These pieces are regions of the viruses’ spike protein, called receptor-binding domains (RBDs), that are crucial for the virus to infect a cell. Mosaic-8 is now being prepared for initial human clinical trials.

(Funded by the National Institutes of Health)
Researchers from Rice University, Vanderbilt University, and the U.S. Department of Energy’s Oak Ridge National Laboratory have developed a system for culturing cancer cell clusters that can shed light on hard-to-study tumor properties. The new zinc oxide-based culturing surface mimics the nanoscale roughness of the lotus leaf surface structure, providing a highly tunable platform for the high-throughput generation of three-dimensional nanoscale tumor models. The superhydrophobic array device can be used to create models for studying the progression of cancer, including metastasis – the stage in the disease when cancerous cells travel through the bloodstream from a primary tumor site to other parts of the body.

(Funded by the National Institutes of Health, the National Science Foundation and the U.S. Department of Defense)
Scientists from the Massachusetts Institute of Technology, Harvard Medical School, Carnegie Mellon University, Georgia Institute of Technology, and the University of California, Riverside, have developed polymeric nanocarriers that can cross plant cell walls, delivering functional proteins directly into the cells with unprecedented efficiency. These nanocarriers are engineered with a high aspect ratio, meaning they are long and thin, which is essential for their ability to cross the plant cell wall. One of the critical findings of the study is that the efficiency of protein delivery highly depends on the size and charge of the nanocarriers: Nanocarriers with a width greater than 14 nanometers or with insufficient positive charge were less effective at penetrating the plant cell wall and delivering their protein cargo.

(Funded by the National Institutes of Health and the National Science Foundation)
Engineers at the University of Virginia have created a drug nanocarrier designed to cure chronic or deadly respiratory diseases by slipping past the lungs’ natural defenses. The engineers successfully demonstrated the nanocarrier’s effectiveness using a device that captures the geometric and biological features of human airways. “We think this innovation not only promises better treatments of lung diseases with reduced side effects, but also opens possibilities for treating conditions affecting mucosal surfaces throughout the body,” said Liheng Cai, one of the engineers involved in this study.